Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mevidalen
- Development stage
- Phase 2
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Mevidalen is a small molecule dopaminergic drug developed for the treatment of Lewy body disease, including Parkinson's disease dementia and dementia with Lewy bodies. It acts as a selective positive allosteric modulator (PAM) of the dopamine D1 receptor, enhancing the affinity and activity of dopamine at this receptor. Mevidalen is orally active, crosses the blood–brain barrier, and has been shown to promote wakefulness in sleep-deprived individuals. Its mechanism amplifies responses to endogenous and exogenous dopamine, potentially improving both cognitive and motor symptoms in patients with Parkinson's disease or Lewy body dementias. The drug is being developed by Eli Lilly & Co., with clinical trials reaching Phase 2 for these indications[1][3][4][5].
- Other names
- mevidalen hydroxybenzoate
02
Targets
DRD1 (Dopamine D1 Receptor)
Beyond the preview
Go deeper on mevidalen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mevidalen.